Ovid therapeutics inc. (OVID)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]
Subsidiary Sale Of Stock [Line Items]
Cash flows from operating activities:
Net loss

-66,691

-60,461

-56,391

-52,719

-52,597

-51,979

-50,039

-46,436

-43,750

-64,806

-61,407

-57,833

-52,970

-22,414

0

0

0

Adjustments to reconcile net loss to cash used in operating activities:
Non-cash research and development expense

-

-

-

-

-

-

-

-

-

25,861

0

0

0

-

-

-

-

Stock-based compensation expense

4,866

5,205

5,810

6,319

6,911

7,063

6,743

6,425

6,774

6,397

6,035

5,755

4,339

3,641

0

0

0

Depreciation and amortization expense

245

255

256

235

191

141

108

94

88

80

91

79

69

56

0

0

0

Change in accrued interest and accretion of discount on short-term investments

-133

-29

35

71

-50

-1

0

0

0

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Prepaid expenses and other current assets

104

-224

-903

2,656

995

1,305

1,488

1,091

692

793

628

102

269

-58

0

0

0

Deferred transaction costs

-

-

-

-

-

-

-

-

-

229

0

0

0

-

-

0

0

Security deposit

-30

-13

8

8

5

-33

-40

-47

-68

-36

0

0

0

-

-

-

-

Related party receivable

-883

531

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Long-term prepaid expenses

-3,024

-2,438

-3,536

-2,062

673

2,192

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

13

-653

591

-1,407

1,548

1,649

3,008

-138

723

1,076

920

2,451

756

186

0

0

0

Accrued expenses

2,330

2,177

-1,147

3,068

-524

1,093

2,677

573

893

1,118

1,019

1,432

2,346

1,238

0

0

0

Related party payable

-

297

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Due from/ to related parties

-

-

-

-

-

-

-

-

-

-7

0

0

1

-50

0

0

0

Net cash used in operating activities

-56,635

-51,090

-45,167

-45,719

-45,498

-45,558

0

0

0

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-21,113

-17,801

0

0

0

Purchases of short-term investments

0

-

-

-

-

50,011

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturities of short-term investments

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

66

57

20

12

30

33

47

45

34

38

34

30

27

30

0

0

0

Software development and other assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Software development and other assets

-

-

-

-

-

-

-

120

17

8

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

-26,196

-30,041

21,909

39,840

39,699

-5,363

0

0

0

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from February Offering, net of offering expenses

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from employee stock purchase plan

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Software development and other costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-213

-188

0

0

0

Payments for transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Proceeds from employee stock purchase plan

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of options

-

-

-

-

-

111

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

55,568

86,539

30,652

30,705

31,196

286

0

0

0

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Offering costs in accrued expenses and accounts payable

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Software development and other costs in accrued expenses and accounts payable

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment in accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments for transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-83,580

-15,023

35,185

38,288

43,660

-21,809

-18,004

0

0

0

ATM [Member]
Proceeds from February Offering, net of offering expenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-